ARK reports 11.79% stake in CRISPR Therapeutics

CRISPR Therapeutics reported a Schedule 13G/A showing 11,313,623 shares beneficially owned (representing 11.79% of the common stock).

Rhea-AI Filing Summary

CRISPR Therapeutics reported a Schedule 13G/A showing 11,313,623 shares beneficially owned (representing 11.79% of the common stock). The filing attributes ownership to ARK Investment Management LLC and Catherine D. Wood, with ARK holding 10,545,920 shares of sole voting power and total dispositive power over 11,313,623 shares. The amendment is signed and dated 04/30/2026. The filing notes ARK Innovation ETF as a client holding more than 5% within ARK's client list.

Insights

Institutional Ownership Analyst

Large passive stake disclosed: ARK and Wood hold 11.79% of CRISPR Therapeutics.

ARK Investment Management LLC and Catherine D. Wood are reported as beneficial owners of 11,313,623 shares, a stake above the 5% threshold that triggers Schedule 13G/A reporting. The breakdown shows ARK holds sole voting power for 10,545,920 shares and sole dispositive power over 11,313,623 shares.

Subsequent trading activity by ARK or the ARK Innovation ETF could affect public float; future public filings may show if this position changes.

Regulatory / Compliance Specialist

The amendment updates beneficial ownership reporting and identifies client-level interest.

The Schedule 13G/A lists ARK and Catherine D. Wood with combined beneficial ownership of 11,313,623 shares (11.79%). The filing includes a disclosure that ARK Innovation ETF is a client holding over 5% within ARK’s client list.

Signatures are dated 04/30/2026; this satisfies the reporting requirement for substantial passive investors under SEC rules reflected in the amendment.

Key Figures

Beneficial ownership: 11,313,623 shares Percent of class: 11.79% ARK sole voting power: 10,545,920 shares +3 more

6 metrics

Beneficial ownership 11,313,623 shares Combined ARK and Catherine D. Wood position

Percent of class 11.79% Percentage of common stock beneficially owned

ARK sole voting power 10,545,920 shares Sole power to vote or to direct the vote

Shared voting power (Wood) 10,754,100 shares Catherine D. Wood shared power to vote

ARK sole dispositive power 11,313,623 shares Sole power to dispose or to direct the disposition

Signature date 04/30/2026 Filing signatures dated

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, investment company

4 terms

Schedule 13G/A regulatory

"Amendment No. 13 ) CRISPR Therapeutics AG Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: ARK and Catherine D. Wood: 11,313,623"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: ARK: 11,313,623"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

investment company financial

"ARK Innovation ETF, a series of a Delaware statutory trust"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/30/2026 - 12:41 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 13)

CRISPR Therapeutics AG

(Name of Issuer)

Common Stock

(Title of Class of Securities)

H17182108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): H17182108

1

Names of Reporting Persons

ARK Investment Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,545,920.00
6	Shared Voting Power 208,180.00
7	Sole Dispositive Power 11,313,623.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,313,623.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.79 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): H17182108

1

Names of Reporting Persons

Catherine D. Wood

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 10,754,100.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,313,623.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,313,623.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.79 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CRISPR Therapeutics AG
(b)	Address of issuer's principal executive offices: Baarerstrasse 14, Zug, V8 CH-6300
Item 2.
(a)	Name of person filing: (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
(b)	Address or principal business office or, if none, residence: ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
(c)	Citizenship: (i) ARK: Delaware (ii) Catherine D. Wood: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: H17182108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: ARK and Catherine D. Wood: 11,313,623
(b)	Percent of class: ARK and Catherine D. Wood: 11.79
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (i) ARK: 10,545,920 (ii) Catherine D. Wood: 0
	(ii) Shared power to vote or to direct the vote: (i) ARK: 208,180 (ii) Catherine D. Wood: 10,754,100
	(iii) Sole power to dispose or to direct the disposition of: (i) ARK: 11,313,623 (ii) Catherine D. Wood: 0
	(iv) Shared power to dispose or to direct the disposition of: (i) ARK: 0 (ii) Catherine D. Wood: 11,313,623
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. No client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Innovation ETF, a series of a Delaware statutory trust.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARK Investment Management LLC

Signature:	/s/ Kellen Carter
Name/Title:	Kellen Carter, Chief Compliance Officer
Date:	04/30/2026

Catherine D. Wood

Signature:	/s/ Catherine D. Wood
Name/Title:	Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:	04/30/2026